Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688488'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -156.33 Med: -30.29 Max: 371.72
Current: 151.35
During the past 10 years, the highest EV-to-EBITDA of Jiangsu Aidea Pharmaceutical Group Co was 371.72. The lowest was -156.33. And the median was -30.29.
SHSE:688488's EV-to-EBITDA is ranked worse than 94.49% of 399
companies
in the Biotechnology industry
Industry Median: 13.7
vs SHSE:688488: 151.35
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Jiangsu Aidea Pharmaceutical Group Co's PE Ratio (TTM) for today is calculated as:
Jiangsu Aidea Pharmaceutical Group Co's share price for today is ¥15.44.
Jiangsu Aidea Pharmaceutical Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-0.012.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Aidea Pharmaceutical Group Co EV-to-EBITDA Chart
SHSE:688488 vs VRTX, REGN, MRNA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Jiangsu Aidea Pharmaceutical Group Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Aidea Pharmaceutical Group Co EV-to-EBITDA vs Biotechnology Industry
Jiangsu Aidea Pharmaceutical Group Co's current Enterprise Value is ¥6,817.3 Mil.
Jiangsu Aidea Pharmaceutical Group Co's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥45.0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) has a EV-to-EBITDA of 151.35 as of Sep. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jiangsu Aidea Pharmaceutical Group Co. According to the industry distribution chart, Jiangsu Aidea Pharmaceutical Group Co ranks #377 out of 399 companies in the Biotechnology industry, placing it in the top 94.5%.
Is Jiangsu Aidea Pharmaceutical Group Co's EV-to-EBITDA too high?
Jiangsu Aidea Pharmaceutical Group Co's current EV-to-EBITDA is 151.35. The Biotechnology industry median EV-to-EBITDA is 13.70. Jiangsu Aidea Pharmaceutical Group Co's value of 151.35 is 1004.7% above this industry median. Based on the distribution chart, Jiangsu Aidea Pharmaceutical Group Co ranks #377 out of 399 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Jiangsu Aidea Pharmaceutical Group Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Aidea Pharmaceutical Group Co's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Jiangsu Aidea Pharmaceutical Group Co ranks #377 out of 399 companies for EV-to-EBITDA. This places Jiangsu Aidea Pharmaceutical Group Co in the lower half of its industry. The industry median EV-to-EBITDA is 13.70. Jiangsu Aidea Pharmaceutical Group Co's value of 151.35 is 1004.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.70, based on 399 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Aidea Pharmaceutical Group Co's current EV-to-EBITDA of 151.35 is 1004.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Jiangsu Aidea Pharmaceutical Group Co. For the Biotechnology industry, the median EV-to-EBITDA is 13.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Aidea Pharmaceutical Group Co's current EV-to-EBITDA is 151.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Aidea Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥19.35, compared to a current price of ¥15.44 — trading 20.2% below its estimated fair value. The current EV-to-EBITDA is 151.35 and 1004.7% above the Biotechnology industry median of 13.70. Jiangsu Aidea Pharmaceutical Group Co's overall GF Score™ is 73/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488), the current EV-to-EBITDA is 151.35 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Aidea Pharmaceutical Group Co (SHSE:688488) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Aidea Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥15.44 is trading 20.2% below its estimated GF Value™ of ¥19.35.
GuruFocus considers Jiangsu Aidea Pharmaceutical Group Co to be Modestly Undervalued.
Key valuation signals for SHSE:688488:
EV-to-EBITDA: 151.35
GF Value™: ¥19.35 vs. price of ¥15.44 (20.2% below fair value)
Industry Position: 1004.7% above the Biotechnology median (#377 of 399)
No single metric tells the full story. See the SHSE:688488 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Aidea Pharmaceutical Group Co Ltd is engaged in the production and sales of human protein products, and also carries out some generic drug business and distributes Abbott's HIV diagnostic equipment and reagents.
73GF Score
Get the complete analysis for SHSE:688488
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688488 has been successfully added to your 
